ClinicalTrials.gg
DrugBiological

Panitumumab clinical trials

Also written ABX-EGF.

studies test it
196
open now
23
in phase 3
23
first study started
2000

How each study uses Panitumumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Panitumumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Sept 2006 · VECTIBIX · BLA 125147 (FDA, Drugs@FDA)
European Union
3 Dec 2007 · Vectibix · EMEA/H/C/000741 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Panitumumab
135
Vectibix
67
MoAb ABX-EGF
11
Monoclonal Antibody ABX-EGF
11
ABX-EGF Monoclonal Antibody
9

Development codes

ABX-EGF
25
RPH-030
1

In one entry with another drug

Given together, or one or the other

Panitumumab-IRDye800
11
Panitumumab IRDye 800
7
RDye800-Panitumumab Conjugate
4
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
2
FOLFOXIRI + Panitumumab
2

Studies by the year they started

193 studies that test it; most in 2010 (33)

Studies that test Panitumumab, by start year
YearStudies
20001
20025
20033
20046
20052
20068
200710
200812
200918
201033
201118
20126
20134
20144
20155
20167
20177
201811
20196
20204
20211
20222
20235
20245
20254
20266

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
37
Phase 2
150
Phase 3
23
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 43 · Other 153

Amgen (34) · M.D. Anderson Cancer Center (6) · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (6) · Vejle Hospital (6) · UNICANCER (5) · Vanderbilt-Ingram Cancer Center (5) · AIO-Studien-gGmbH (5) · Grupo Espanol Multidisciplinario del Cancer Digestivo (5)

Often tested with

Tested in the same studies.

Irinotecan (18) · Oxaliplatin (16) · Fluorouracil (13) · IRDye800 (13) · Bevacizumab (12) · Capecitabine (11) · FOLFIRI Regimen (8) · Carboplatin (8)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 8

Studies that test Panitumumab.

Studies

Open first, then newest update. How each study uses Panitumumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 196

See all 196 studies that test Panitumumab →

Given beside what is tested · 32 — Panitumumab is usual care or a partner of the new treatment

Showing 20 of 32.

As the comparator · 5 — what is tested is compared with Panitumumab

Codes

What other systems call Panitumumab · ClinicalTrials.gg INT006741

  • MeSH (NLM) D000077544PanitumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 6A901E312APANITUMUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 263034Confirmed FDA, Wikidata
  • Wikidata Q417775panitumumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1857PanitumumabOne source FDA
  • DrugBank DB01269One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.